Skip to main content
Top
Published in: Journal of Clinical Immunology 1/2013

Open Access 01-01-2013

In Vitro and In Vivo Studies of IgG-derived Treg Epitopes (Tregitopes): A Promising New Tool for Tolerance Induction and Treatment of Autoimmunity

Authors: Leslie P. Cousens, Nader Najafian, Federico Mingozzi, Wassim Elyaman, Bruce Mazer, Leonard Moise, Timothy J. Messitt, Yan Su, Mohamed Sayegh, Katherine High, Samia J. Khoury, David W. Scott, Anne S. De Groot

Published in: Journal of Clinical Immunology | Special Issue 1/2013

Login to get access

Abstract

Tregitopes are regulatory T cell epitopes derived from immunoglobulin G (IgG) that stimulate CD25+ FoxP3+ T cells to expand. In conjunction with these Tregs, Tregitopes can prevent, treat, and even cure autoimmune disease in mouse models, suppress allo-specific responses in murine transplant models, inhibit CD8+ T cell responses to recombinant adeno-associated virus (AAV) gene transfer vectors, and induce adaptive Tregs in DO11.10 mice. In this review of recent Tregitope studies, we summarize their effects in vitro and describe recent comparisons between intravenous IgG (IVIG) and Tregitopes in standard in vivo immune tolerance models. Further investigations of the mechanism of action of Tregitopes in the preclinical models described here will lead to clinical trials where Tregitopes may have the potential to alter the treatment of autoimmune disease, transplantation, and allergy, and to improve the efficiency of gene and protein replacement therapies.
Literature
1.
go back to reference De Groot AS, Moise L, McMurry JA, Wambre E, Van Overtvelt L, Moingeon P, et al. Activation of natural regulatory T cells by IgG Fc-derived peptide “Tregitopes”. Blood. 2008;112(8):3303–11.PubMedCrossRef De Groot AS, Moise L, McMurry JA, Wambre E, Van Overtvelt L, Moingeon P, et al. Activation of natural regulatory T cells by IgG Fc-derived peptide “Tregitopes”. Blood. 2008;112(8):3303–11.PubMedCrossRef
2.
go back to reference Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol. 2003;3(3):253–7.PubMedCrossRef Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol. 2003;3(3):253–7.PubMedCrossRef
3.
go back to reference Durinovic-Belló I, Rosinger S, Olson JA, Congia M, Ahmad RC, Rickert M, et al. DRB1*0401-restricted human T cell clone specific for the major proinsulin73-90 epitope expresses a down-regulatory T helper 2 phenotype. Proc Natl Acad Sci USA. 2006;103(31):11683–8.PubMedCrossRef Durinovic-Belló I, Rosinger S, Olson JA, Congia M, Ahmad RC, Rickert M, et al. DRB1*0401-restricted human T cell clone specific for the major proinsulin73-90 epitope expresses a down-regulatory T helper 2 phenotype. Proc Natl Acad Sci USA. 2006;103(31):11683–8.PubMedCrossRef
4.
go back to reference Sumida T, Kato T, Hasunuma T, Maeda T, Nishioka K, Matsumoto I. Regulatory T cell epitope recognized by T cells from labial salivary glands of patients with Sjögren's syndrome. Arthritis Rheum. 1997;40(12):2271–3.PubMedCrossRef Sumida T, Kato T, Hasunuma T, Maeda T, Nishioka K, Matsumoto I. Regulatory T cell epitope recognized by T cells from labial salivary glands of patients with Sjögren's syndrome. Arthritis Rheum. 1997;40(12):2271–3.PubMedCrossRef
5.
go back to reference Baxevanis CN, Ioannides CG, Reclos GJ, Papamichail M. Evidence for distinct epitopes on human IgG with T cell proliferative and suppressor function. Eur J Immunol. 1986;16(8):1013–6.PubMedCrossRef Baxevanis CN, Ioannides CG, Reclos GJ, Papamichail M. Evidence for distinct epitopes on human IgG with T cell proliferative and suppressor function. Eur J Immunol. 1986;16(8):1013–6.PubMedCrossRef
6.
go back to reference Zambidis ET, Scott DW. Epitope-specific tolerance induction with an engineered immunoglobulin. Proc Natl Acad Sci USA. 1996;93(10):5019–24.PubMedCrossRef Zambidis ET, Scott DW. Epitope-specific tolerance induction with an engineered immunoglobulin. Proc Natl Acad Sci USA. 1996;93(10):5019–24.PubMedCrossRef
7.
go back to reference Cousens LP, Su Y, McClaine E, Li X, Terry F, Cohen T, et al. Application of IgG-derived natural Treg epitopes (IgG Tregitopes) to antigen-specific tolerance induction in a murine model of Type 1 diabetes. 2011; Submitted for publication. Cousens LP, Su Y, McClaine E, Li X, Terry F, Cohen T, et al. Application of IgG-derived natural Treg epitopes (IgG Tregitopes) to antigen-specific tolerance induction in a murine model of Type 1 diabetes. 2011; Submitted for publication.
8.
go back to reference Smith T. Active immunity produced by so called balanced or neutral mixtures of diphtheria toxin and antitoxin. J Exp Med. 1909;11(2):241–56.PubMedCrossRef Smith T. Active immunity produced by so called balanced or neutral mixtures of diphtheria toxin and antitoxin. J Exp Med. 1909;11(2):241–56.PubMedCrossRef
9.
go back to reference Maddur MS, Othy S, Hegde P, Vani J, Lacroix-Desmazes S, Bayry J, et al. Immunomodulation by intravenous immunoglobulin: role of regulatory T cells. J Clin Immunol. 2010;30 Suppl 1:S4–8.PubMedCrossRef Maddur MS, Othy S, Hegde P, Vani J, Lacroix-Desmazes S, Bayry J, et al. Immunomodulation by intravenous immunoglobulin: role of regulatory T cells. J Clin Immunol. 2010;30 Suppl 1:S4–8.PubMedCrossRef
10.
go back to reference Jordan SC, Toyoda M, Vo AA. Regulation of immunity and inflammation by intravenous immunoglobulin: relevance to solid organ transplantation. Expert Rev Clin Immunol. 2011;7(3):341–8.PubMedCrossRef Jordan SC, Toyoda M, Vo AA. Regulation of immunity and inflammation by intravenous immunoglobulin: relevance to solid organ transplantation. Expert Rev Clin Immunol. 2011;7(3):341–8.PubMedCrossRef
11.
go back to reference Zeitler H, Ulrich-Merzenich G, Hess L, Konsek E, Unkrig C, Walger P, et al. Treatment of acquired hemophilia by the Bonn-Malmo Protocol: documentation of an in vivo immunomodulating concept. Blood. 2005;105(6):2287–93.PubMedCrossRef Zeitler H, Ulrich-Merzenich G, Hess L, Konsek E, Unkrig C, Walger P, et al. Treatment of acquired hemophilia by the Bonn-Malmo Protocol: documentation of an in vivo immunomodulating concept. Blood. 2005;105(6):2287–93.PubMedCrossRef
12.
go back to reference Kubisz P, Plamenová I, Hollý P, Stasko J. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy. Med Sci Monit. 2009;15(6):CS105-11. Kubisz P, Plamenová I, Hollý P, Stasko J. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy. Med Sci Monit. 2009;15(6):CS105-11.
13.
go back to reference Jordan SC, Vo AA, Peng A, Toyoda M, Tyan D. Intravenous gammaglobulin (IVIG): a novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients. Am J Transplant. 2006;6(3):459–66.PubMedCrossRef Jordan SC, Vo AA, Peng A, Toyoda M, Tyan D. Intravenous gammaglobulin (IVIG): a novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients. Am J Transplant. 2006;6(3):459–66.PubMedCrossRef
14.
go back to reference Zandman-Goddard G, Krauthammer A, Levy Y, Langevitz P, Shoenfeld Y. Long-term therapy with intravenous immunoglobulin is beneficial in patients with autoimmune diseases. Clin Rev Allergy Immunol. 2011 Jul 6. [Epub ahead of print]. Zandman-Goddard G, Krauthammer A, Levy Y, Langevitz P, Shoenfeld Y. Long-term therapy with intravenous immunoglobulin is beneficial in patients with autoimmune diseases. Clin Rev Allergy Immunol. 2011 Jul 6. [Epub ahead of print].
15.
go back to reference Bystryn JC, Jiao D. IVIg selectively and rapidly decreases circulating pathogenic autoantibodies in pemphigus vulgaris. Autoimmunity. 2006;39(7):601–7.PubMedCrossRef Bystryn JC, Jiao D. IVIg selectively and rapidly decreases circulating pathogenic autoantibodies in pemphigus vulgaris. Autoimmunity. 2006;39(7):601–7.PubMedCrossRef
16.
go back to reference Anthony RM, Wermeling F, Karlsson MC, Ravetch JV. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci USA. 2008;105(50):19571–8.PubMedCrossRef Anthony RM, Wermeling F, Karlsson MC, Ravetch JV. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci USA. 2008;105(50):19571–8.PubMedCrossRef
17.
go back to reference Karlsson MC, Wernersson S, Diaz de Ståhl T, Gustavsson S, Heyman B. Efficient IgG-mediated suppression of primary antibody responses in Fc-gamma receptor-deficient mice. Proc Natl Acad Sci USA. 1999;96(5):2244–9.PubMedCrossRef Karlsson MC, Wernersson S, Diaz de Ståhl T, Gustavsson S, Heyman B. Efficient IgG-mediated suppression of primary antibody responses in Fc-gamma receptor-deficient mice. Proc Natl Acad Sci USA. 1999;96(5):2244–9.PubMedCrossRef
18.
go back to reference Kirschbaum J, Forschner K, Rasche C, Worm M. Modulation of lymphocyte phenotype and function by immunoglobulins. Brit J Dermatol. 2006;154(2):225–30.CrossRef Kirschbaum J, Forschner K, Rasche C, Worm M. Modulation of lymphocyte phenotype and function by immunoglobulins. Brit J Dermatol. 2006;154(2):225–30.CrossRef
19.
go back to reference Tha-In T, Metselaar HJ, Bushell AR, Kwekkeboom J, Wood KJ. Intravenous immunoglobulins promote skin allograft acceptance by triggering functional activation of CD4 + Foxp3+ T cells. Transplantation. 2010;89(12):1446–55.PubMedCrossRef Tha-In T, Metselaar HJ, Bushell AR, Kwekkeboom J, Wood KJ. Intravenous immunoglobulins promote skin allograft acceptance by triggering functional activation of CD4 + Foxp3+ T cells. Transplantation. 2010;89(12):1446–55.PubMedCrossRef
20.
go back to reference Ephrem A, Chamat S, Miquel C, Fisson S, Mouthon L, Caligiuri G, et al. Expansion of CD4 + CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood. 2008;111(2):715–22.PubMedCrossRef Ephrem A, Chamat S, Miquel C, Fisson S, Mouthon L, Caligiuri G, et al. Expansion of CD4 + CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood. 2008;111(2):715–22.PubMedCrossRef
21.
go back to reference Lopez M, Clarkson MR, Albin M, Sayegh MH, Najafian N. A novel mechanism of action for anti-thymocyte globulin: induction of CD4 + CD25 + Foxp3+ regulatory T cells. J Am Soc Nephrol. 2006;17(10):2844–53.PubMedCrossRef Lopez M, Clarkson MR, Albin M, Sayegh MH, Najafian N. A novel mechanism of action for anti-thymocyte globulin: induction of CD4 + CD25 + Foxp3+ regulatory T cells. J Am Soc Nephrol. 2006;17(10):2844–53.PubMedCrossRef
22.
go back to reference Chi LJ, Wang HB, Zhang Y, Wang WZ. Abnormality of circulating CD4(+)CD25(+) regulatory T cell in patients with Guillain-Barré syndrome. J Neuroimmunol. 2007;192(1–2):206–14.PubMedCrossRef Chi LJ, Wang HB, Zhang Y, Wang WZ. Abnormality of circulating CD4(+)CD25(+) regulatory T cell in patients with Guillain-Barré syndrome. J Neuroimmunol. 2007;192(1–2):206–14.PubMedCrossRef
23.
go back to reference Kuo TT, Baker K, Yoshida M, Qiao SW, Aveson VG, Lencer WI, et al. Neonatal Fc receptor: from immunity to therapeutics. J Clin Immunol. 2010;30(6):777–89.PubMedCrossRef Kuo TT, Baker K, Yoshida M, Qiao SW, Aveson VG, Lencer WI, et al. Neonatal Fc receptor: from immunity to therapeutics. J Clin Immunol. 2010;30(6):777–89.PubMedCrossRef
24.
go back to reference Qiao SW, Kobayashi K, Johansen FE, Sollid LM, Andersen JT, Milford E, et al. Dependence of antibody-mediated presentation of antigen on FcRn. Proc Natl Acad Sci USA. 2008;105(27):9337–42.PubMedCrossRef Qiao SW, Kobayashi K, Johansen FE, Sollid LM, Andersen JT, Milford E, et al. Dependence of antibody-mediated presentation of antigen on FcRn. Proc Natl Acad Sci USA. 2008;105(27):9337–42.PubMedCrossRef
25.
go back to reference Anthony RM, Nimmerjahn F, Ashline DJ, Reinhold VN, Paulson JC, Ravetch JV. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science. 2008;320(5874):373–6.PubMedCrossRef Anthony RM, Nimmerjahn F, Ashline DJ, Reinhold VN, Paulson JC, Ravetch JV. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science. 2008;320(5874):373–6.PubMedCrossRef
26.
go back to reference Bayry J, Bansal K, Kazatchkine MD, Kaveri SV. DC-SIGN and alpha2,6-sialylated IgG Fc interaction is dispensable for the anti-inflammatory activity of IVIg on human dendritic cells. Proc Natl Acad Sci USA. 2009;106(9):E24.PubMedCrossRef Bayry J, Bansal K, Kazatchkine MD, Kaveri SV. DC-SIGN and alpha2,6-sialylated IgG Fc interaction is dispensable for the anti-inflammatory activity of IVIg on human dendritic cells. Proc Natl Acad Sci USA. 2009;106(9):E24.PubMedCrossRef
27.
go back to reference Hahn BH, Singh RP, La Cava A, Ebling FM. Tolerogenic treatment of lupus mice with consensus peptide induces Foxp3-expressing, apoptosis-resistant, TGFbeta-secreting CD8+ T cell suppressors. J Immunol. 2005;175(11):7728–37.PubMed Hahn BH, Singh RP, La Cava A, Ebling FM. Tolerogenic treatment of lupus mice with consensus peptide induces Foxp3-expressing, apoptosis-resistant, TGFbeta-secreting CD8+ T cell suppressors. J Immunol. 2005;175(11):7728–37.PubMed
28.
go back to reference Sharabi A, Zinger H, Zborowsky M, Sthoeger ZM, Mozes E. A peptide based on the complementarity-determining region 1 of an autoantibody ameliorates lupus by up-regulating CD4 + CD25+ cells and TGF-beta. Proc Natl Acad Sci USA. 2006;103(23):8810–5.PubMedCrossRef Sharabi A, Zinger H, Zborowsky M, Sthoeger ZM, Mozes E. A peptide based on the complementarity-determining region 1 of an autoantibody ameliorates lupus by up-regulating CD4 + CD25+ cells and TGF-beta. Proc Natl Acad Sci USA. 2006;103(23):8810–5.PubMedCrossRef
29.
go back to reference Sharabi A, Dayan M, Zinger H, Mozes E. A new model of induced experimental systemic lupus erythematosus (SLE) in pigs and its amelioration by treatment with a tolerogenic peptide. J Clin Immunol. 2010;30(1):34–44.PubMedCrossRef Sharabi A, Dayan M, Zinger H, Mozes E. A new model of induced experimental systemic lupus erythematosus (SLE) in pigs and its amelioration by treatment with a tolerogenic peptide. J Clin Immunol. 2010;30(1):34–44.PubMedCrossRef
30.
go back to reference Mozes E, Sharabi A. A novel tolerogenic peptide, hCDR1, for the specific treatment of systemic lupus erythematosus. Autoimmun Rev. 2010;10(1):22–6. Epub 2010 Jul 23. Mozes E, Sharabi A. A novel tolerogenic peptide, hCDR1, for the specific treatment of systemic lupus erythematosus. Autoimmun Rev. 2010;10(1):22–6. Epub 2010 Jul 23.
31.
go back to reference De Groot AS, Martin W. Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics. Clin Immunol. 2009;131(2):189–201.PubMedCrossRef De Groot AS, Martin W. Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics. Clin Immunol. 2009;131(2):189–201.PubMedCrossRef
32.
go back to reference D'Addio F, Boenisch O, Wattanabe T, De Groot AS, Sayegh, MH, Najafian N. Immuno-modulatory functions of a novel IgG Fc-derived peptides, Tregitopes, in alloimmunity. Presented at the American Transplant Conference; May 30−June 3, 2009; Boston, MA, USA. D'Addio F, Boenisch O, Wattanabe T, De Groot AS, Sayegh, MH, Najafian N. Immuno-modulatory functions of a novel IgG Fc-derived peptides, Tregitopes, in alloimmunity. Presented at the American Transplant Conference; May 30−June 3, 2009; Boston, MA, USA.
33.
go back to reference Mazer B, Massoud AH, Ablona A, Langelier AB, Cousens L, De Groot AS. Tregitopes recapitulate action of IVIg by abrogating OVA-induced allergic airways disease via induction of T regulatory cells (Treg). Presented at the 2nd International Forum on Immunoglobulin Research; September 14–17, 2011; Barcelona, Spain. Mazer B, Massoud AH, Ablona A, Langelier AB, Cousens L, De Groot AS. Tregitopes recapitulate action of IVIg by abrogating OVA-induced allergic airways disease via induction of T regulatory cells (Treg). Presented at the 2nd International Forum on Immunoglobulin Research; September 14–17, 2011; Barcelona, Spain.
34.
go back to reference Mingozzi F, Finn JD, Zhou S, Hui DJ, Pien GC, Basner-Tschakarjan E, et al. Suppression of CTL responses against AAV-capsid epitopes by peptide-induced regulatory T cells. Presented at the 51st Annual Meeting of the American Society for Hematology; December 7, 2009; New Orleans, LA, USA. Presentation #377. Mingozzi F, Finn JD, Zhou S, Hui DJ, Pien GC, Basner-Tschakarjan E, et al. Suppression of CTL responses against AAV-capsid epitopes by peptide-induced regulatory T cells. Presented at the 51st Annual Meeting of the American Society for Hematology; December 7, 2009; New Orleans, LA, USA. Presentation #377.
35.
go back to reference Elyaman W, Khoury SJ, Scott DW, De Groot AS. Potential application of tregitopes as immunomodulating agents in multiple sclerosis. Neurol Res Int. 2011; doi:10.1155/2011/256460. Elyaman W, Khoury SJ, Scott DW, De Groot AS. Potential application of tregitopes as immunomodulating agents in multiple sclerosis. Neurol Res Int. 2011; doi:10.​1155/​2011/​256460.
36.
go back to reference Wigren M, Kolbus D, Dunér P, Ljungcrantz I, Söderberg I, Björkbacka H, et al. Evidence for a role of regulatory T cells in mediating the atheroprotective effect of apolipoprotein B peptide vaccine. J Intern Med. 2011; doi: 10.1111/j.1365-2796.2010.02311.x. Wigren M, Kolbus D, Dunér P, Ljungcrantz I, Söderberg I, Björkbacka H, et al. Evidence for a role of regulatory T cells in mediating the atheroprotective effect of apolipoprotein B peptide vaccine. J Intern Med. 2011; doi: 10.​1111/​j.​1365-2796.​2010.​02311.​x.
38.
go back to reference Nishio J, Feuerer M, Wong J, Mathis D, Benoist C. Anti-CD3 therapy permits regulatory T cells to surmount T cell receptor–specified peripheral niche constraints. J Exp Med. 2010;207(9):1879–89.PubMedCrossRef Nishio J, Feuerer M, Wong J, Mathis D, Benoist C. Anti-CD3 therapy permits regulatory T cells to surmount T cell receptor–specified peripheral niche constraints. J Exp Med. 2010;207(9):1879–89.PubMedCrossRef
39.
go back to reference Grinberg-Bleyer Y, Baeyens A, You S, Elhage R, Fourcade G, Gregoire S, et al. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med. 2010;207(9):1871–8.PubMedCrossRef Grinberg-Bleyer Y, Baeyens A, You S, Elhage R, Fourcade G, Gregoire S, et al. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med. 2010;207(9):1871–8.PubMedCrossRef
Metadata
Title
In Vitro and In Vivo Studies of IgG-derived Treg Epitopes (Tregitopes): A Promising New Tool for Tolerance Induction and Treatment of Autoimmunity
Authors
Leslie P. Cousens
Nader Najafian
Federico Mingozzi
Wassim Elyaman
Bruce Mazer
Leonard Moise
Timothy J. Messitt
Yan Su
Mohamed Sayegh
Katherine High
Samia J. Khoury
David W. Scott
Anne S. De Groot
Publication date
01-01-2013
Publisher
Springer US
Published in
Journal of Clinical Immunology / Issue Special Issue 1/2013
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-012-9762-4

Other articles of this Special Issue 1/2013

Journal of Clinical Immunology 1/2013 Go to the issue